Tiny molecule, big power: multi-target approach for curcumin in diabetic cardiomyopathy
… of diabetes, cardiovascular complications are considered to contribute largely to the death
rate of diabetes because of diabetic cardiomyopathy (DCM), sudden cardiac death, and …
rate of diabetes because of diabetic cardiomyopathy (DCM), sudden cardiac death, and …
Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapy
… Diabetic complications are among the largely exigent health problems currently. … complications,
including diabetic cardiomyopathy (DCM), account for more than 80% of diabetic deaths. …
including diabetic cardiomyopathy (DCM), account for more than 80% of diabetic deaths. …
Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfuntion
BR Goyal, AA Mehta - Human & experimental toxicology, 2013 - journals.sagepub.com
… hearts, with increased LV end-diastolic pressure and reduced LV developed pressure,
cardiac output, and cardiac power. The rate of glycolysis from exogenous glucose in …
cardiac output, and cardiac power. The rate of glycolysis from exogenous glucose in …
Bioactive compounds in diabetic cardiomyopathy: current approaches and potential diagnostic and therapeutic targets
SK Kotturu, VVS Uddandrao, S Ghosh… - … Agents in Medicinal …, 2021 - ingentaconnect.com
… ; Iglewski, M.; Shelton, JM; Gerard, RD; Rothermel, BA; Gillette, TG; Lavandero, S.; Hill, JA
Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J. Clin. …
Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J. Clin. …
Power spectral analysis of heart-rate variations improves assessment of diabetic cardiac autonomic neuropathy
F Bellavere, I Balzani, G De Masi, M Carraro… - Diabetes, 1992 - Am Diabetes Assoc
… power between diabetic subjects without CAN and those with mild and severe CAN; a
significant difference in the HFB power … three classes of diabetic subjects in LFB power. Because …
significant difference in the HFB power … three classes of diabetic subjects in LFB power. Because …
Small engine, big power: microRNAs as regulators of cardiac diseases and regeneration
… In our recent study, we demonstrated that miRNA-155 regulates cardiac fibrosis in diabetic
(db/db) mice, possibly via inhibition of anti-fibrotic Sloan–Kettering Institute proto-oncogene (…
(db/db) mice, possibly via inhibition of anti-fibrotic Sloan–Kettering Institute proto-oncogene (…
… diabetic cardiomyopathy: relation of left ventricular diastolic dysfunction to cardiac autonomic neuropathy in men with uncomplicated well-controlled type 2 diabetes
P Poirier, P Bogaty, F Philippon, C Garneau, C Fortin… - Metabolism, 2003 - Elsevier
… , power in the low frequency (LF: 0.04 to 0.15 Hz), an index of both sympathetic and
parasympathetic activity, and power … ratio is the power in low frequency divided by the power in …
parasympathetic activity, and power … ratio is the power in low frequency divided by the power in …
Current status and challenges of NRF2 as a potential therapeutic target for diabetic cardiomyopathy
ZD Ge, Q Lian, X Mao, Z Xia - International heart journal, 2019 - jstage.jst.go.jp
… therapeutic effects on diabetic cardiomyopathy in animal models of diabetic cardiomyopathy.
Targeting NRF2 … Tiny molecule, big power: Multi-target approach for curcumin in diabetic …
Targeting NRF2 … Tiny molecule, big power: Multi-target approach for curcumin in diabetic …
C Repurposing the diabetes drug metformin for treatment of adverse left ventricular remodelling in cardiovascular disease
Abstracts Page 1 Methods We compared abundance of cMyC to hs-cTn by spiking
cardiomyocytes/cardiac tissue into aliquots of human serum. We evaluated the clinical utility of cMyC …
cardiomyocytes/cardiac tissue into aliquots of human serum. We evaluated the clinical utility of cMyC …
Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides
S Romano, M Di Mauro, S Fratini, L Guarracini… - Cardiovascular …, 2010 - Springer
… of diabetes in patients with chronic heart failure is around 30% and close to 50% in those with
acute HF [3–5] The first stage of diabetic cardiomyopathy … group to achieve a power of 80% …
acute HF [3–5] The first stage of diabetic cardiomyopathy … group to achieve a power of 80% …
相关搜索
- natural products diabetic cardiomyopathy
- molecular mechanisms diabetic cardiomyopathy
- big power cardiac diseases
- management of diabetic cardiomyopathy
- diabetic cardiomyopathy development
- assessment of diabetic cardiac autonomic neuropathy
- preclinical diabetic cardiomyopathy
- signaling in diabetic cardiomyopathy
- asymptomatic diabetic cardiomyopathy
- potential therapeutic target for diabetic cardiomyopathy
- diabetic cardiomyopathy and nephropathy
- big power tiny molecule
- progression of diabetic cardiomyopathy
- pathophysiological fundamentals diabetic cardiomyopathy
- comprehensive updated review diabetic cardiomyopathy
- early diagnostic biomarkers diabetic cardiomyopathy